Letairis Approval History
FDA Approved: Yes (First approved June 15, 2007)
Brand name: Letairis
Generic name: ambrisentan
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: Pulmonary Hypertension
Letairis (ambrisentan) is an endothelin receptor antagonist (ERA) indicated for the once-daily oral treatment of pulmonary arterial hypertension.
Development History and FDA Approval Process for Letairis
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.